March 2, 2012 Mr. A.J. Kazimi Nashville, TN 37203 Re: Employment of A.J. Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc. Dear A.J.:Cumberland Pharmaceuticals Inc • March 7th, 2012 • Pharmaceutical preparations • Tennessee
Effective January 1st, 2012, this letter agreement (the “Agreement”) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the “Company”). In consideration of your appointment as Chief Executive Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:
Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment which has been filed separately with the SEC. PACKAGING AGREEMENTPackaging Agreement • March 7th, 2012 • Cumberland Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Agreement (“Agreement”) is entered into as of the 1st day of November, 2011 (the “Effective Date”), by and among Mylan Institutional Inc. (formerly known as UDL Laboratories, Inc.), a corporation organized under the laws of the State of Illinois, having an address of 12720 Dairy Ashford, Sugar Land, Texas, USA 77478, Mylan Pharmaceuticals Inc., a corporation organized under the laws of the State of West Virginia, having an address of 781 Chestnut Ridge Road, Morgantown, West Virginia, USA 26505 (Mylan Institutional Inc. and Mylan Pharmaceuticals Inc. shall be collectively referred to herein as “Mylan”) and Cumberland Pharmaceuticals Inc., a corporation organized under the laws of the State of Tennessee with a place of business at 2525 West End Avenue, Suite 950, Nashville, Tennessee, USA 37203 (hereinafter referred to as “Cumberland”). Mylan and Cumberland may each be referred to herein individually as a “Party” and collectively as the “Parties.”
